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Abstract
Neuronal surface autoantibodies (NSAbs) against various antigens cause autoimmune encephalitis. Some of these
antigens are also involved in the pathology of depression and anxiety. To study whether NSAbs are more common in
plasma of individuals with depression and anxiety than in controls, and to investigate if NSAbs correlate with disease
status, plasma samples of 819 individuals with a current diagnosis of depression and/or anxiety, 920 in remission and
492 individuals without these disorders were included in this study. Samples were tested by a combination of
immunohistochemistry (IHC), staining on live rat hippocampus neurons and cell-based assay (CBA). By IHC, 50 (2.2%)
samples showed immunoreactivity to rat brain tissue, with no significant differences between the aforementioned
groups (22/819 vs 18/920 vs 11/492, P > 0.99). In addition, eight IHC positive samples were positive for NSAbs on live
neurons (7/819 vs 0/920 vs 1/492, P= 0.006). The IHC-staining patterns of these eight samples were atypical for
autoimmune encephalitis and accordingly, they tested negative for known NSAbs by CBA. No obvious difference in
the clinical characteristics between individuals with or without NSAbs was observed. In conclusion, novel NSAbs were
rare but predominately found in patients with current anxiety or depression indicating they might affect mental health
in a small group of patients.
Introduction
Depression and anxiety disorders are among the most
common illnesses and their economic burden ranks
among the top-five of all diseases1,2. Although these dis-
orders may share a similar cluster of symptoms, they are
believed to be caused by heterogeneous pathophysiologic
mechanisms. Immune dysregulation has been observed in
patients with depression and anxiety3–6 and a high pre-
valence of these disorders was found in autoimmune
diseases7–10, which may suggest a link between auto-
immunity and depression or anxiety.
It has been reported that certain neuronal surface
autoantibodies (NSAbs) are associated with isolated
symptoms of psychosis11. These autoantibodies are
pathogenic by degrading or blocking neurotransmitter
receptors, ion channels, or associated proteins, ultimately
leading to dysfunction of neural signal transduction in
most cases12. Neurotransmitter transporters and recep-
tors are clearly implicated in the pathology of depression
and anxiety and they are targeted therapeutically with
anti-depressant drugs13,14. Thus, there is a good reason to
consider the possibility that certain NSAbs may constitute
one of the putative causes of depression and anxiety15–17.
Studies investigating the prevalence of NSAbs in psy-
chiatric diseases have mainly focused on autoantibodies
against the N-methyl-D-aspartate receptor (NMDAR) in
psychotic disorders but the possible role of neuronal
autoantibodies in depression and anxiety has received
little attention thus far18–23. A few studies have included
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depression and anxiety cohorts but have not revealed any
instances of specific neuronal autoantibodies related to
these disorders24,25. Limited cohort size and the lack of
further validation of the results, led to inconclusive
evidence.
Autoimmune encephalitis caused by NSAb is com-
monly diagnosed by cell-based assays (CBA), including
fixed and live CBA, which are designed to detect auto-
antibodies to known, well-defined antigens. When
extending neuronal autoantibody detection from neuro-
logical disorders to new disorders (as in this case
depression or anxiety), using methods that can also detect
novel neuronal antibodies would be preferable. Therefore,
immunohistochemistry (IHC) using rat brain tissue,
optimized for the preservation of cell-surface antigens, or
cultured rat neurons, are promising techniques26, albeit
with the limitation that only cross-reactive NSAbs with
human antigens would be detected by these methods.
In this study, we investigated autoantibodies binding to
brain tissue, with a focus on NSAbs in the plasma from a
large cohort of patients with depression and/or anxiety as
well as from control individuals. We followed a tandem
procedure, combining different methods including IHC
on rat brain, staining on live-cultured rat hippocampal
neurons and CBA as reported27.
Material and methods
Participants and samples
The Netherlands Study of Depression and Anxiety
(NESDA) is an ongoing longitudinal cohort study designed
to investigate the course of depression and anxiety dis-
orders for several years. The inclusion and exclusion cri-
teria were described28. Participants were recruited from
primary care practices and specialized mental health
institutions in the regions of Amsterdam, Leiden and
Groningen, Drenthe and Friesland of the Netherlands. In
brief, 2981 participants were included at baseline (Wave 1),
2596 were available at the 2-year follow-up (Wave 3) and
2256 at the 6-year follow-up (Wave 5).
The current study initially used all available plasma
samples collected by NESDA at Wave 3 and the corre-
sponding clinical information. The study included 819
individuals with a current diagnosis of depression and/or
anxiety, 920 in remission and 492 individuals without
these disorders. If individuals tested positive by staining
on live neurons at Wave 3, we then also retrieved their
clinical information and plasma samples fromWave 1 and
Wave 5. The ethical committee of participating uni-
versities approved the research protocol and all respon-
dents provided written informed consent. The Composite
Interview Diagnostic Instrument—lifetime version 2.1—
was used to diagnose depression and anxiety disorders
according to the Diagnostic and Statistical Manual of
Mental Disorders—Fourth Edition algorithms. The whole
cohort consisted of individuals with depression and/ or
anxiety disorders, current (depression and /or anxiety
present in the 6 months prior to assessment) or in
remission (depression and/or anxiety diagnosed earlier in
life but not present in the 6 months prior to assessment),
and controls without these disorders. Details are given in
Table 1. Plasma samples were stored at −80 °C. Working
aliquoted samples were kept at −20 °C.
Serological analyses
A scheme of the workflow is shown in Supplementary
Fig. 1.
Immunohistochemistry
Fresh adult rat brains (Lewis, male, 12 weeks) were fixed
in 4% paraformaldehyde for 1 h at 4 °C, dehydrated in 30%
sucrose for 48 h at 4 °C, frozen in liquid nitrogen and cut
into 5–7 µm thick sagittal serial sections. These sections
were incubated at room temperature with 0.3% H2O2 for
15minutes and then with 5% goat serum for 1 h. Subse-
quently, they were incubated with 200 µl plasma from the
NESDA cohort (1:200 diluted in 5% goat serum) overnight
at 4 °C and subsequently with biotinylated goat anti-
human IgG Fcγ (1:3200 in 5% goat serum, Jackson
Immunoreserach, #109-066-008) for 2 h at room tem-
perature. Each step was followed by three washing steps
with phosphate-buffered saline. The reactivity was visua-
lized using avidin-biotin-peroxidase (Vector laboratory,
Inc., # PK 6100) and 3,3-diaminobenzidine (Sigma,
#868272-85-9). After dehydration, slides were mounted
using dibutyl phthalate in xylene (Klinipath, #C933401) or
Entellan (Millipore Sigma, #1.07961.0100). Each staining
included a positive control serum from patients with
autoimmune encephalitis and autoantibodies to NMDAR,
α-amino-3 hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR) or dipeptidyl-peptide-like protein 6
(DPPX), and a negative control from a healthy individual.
Images of rat brain IHC were taken by the iScan HT slide
scanner (Ventana; ×20 objective) and visually graded 0–3
(Ventana Image Viewer) for the hippocampal immunor-
eactivity of plasma IgG, based on the intensity and con-
trast of the staining. All samples were randomized and
coded before the autoantibody test. Investigators were
blinded to the code until the scoring was completed. IHC
was also used to define the detected autoantibody titers.
For details, see Supplementary Methods.
Cell-based assays
Fixed CBA
To test autoantibodies to known neuronal antigens,
including NMDAR, AMPAR, γ-aminobutyric acid
receptor subunits A and B (GABAAR, GABABR), leucine-
rich glioma-inactivated 1 (LGI1), contactin-associated
protein-like 2 (CASPR2), glutamic acid decarboxylase 65
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and 67 (GAD65 and GAD67), HEK cells (checked routi-
nely for mycoplasma contamination) were transfected
with plasmids carrying the recombinant cDNA encoding
these proteins. The source of the plasmids is described in
supplementary methods. HEK293 cells were plated on
coverslips and transfected (see supplementary methods).
Cells were fixed in 3.6% formaldehyde (TAAB, #F006) for
10minutes and permeabilized with 0.3% Triton-X-100 for
10minutes. After blocking with 1% bovine serum albumin
(BSA) for 1 h, cells were co-incubated with human sera
Table 1 The demographic characteristics of the NESDA cohort (at the 2-year follow-up).
Clinical values Current depression/anxietya
(n= 819)
Remitted depression/anxietyb
(n= 920)
Control group
(n= 492)
P valuec
Mean age (SD) 44.9 (12.3) 44.5 (13.2) 43.6 (14.6) 0.22
Age range (y) 19–66 19–68 20–66
Female (%) 552 (67.4%) 606 (65.9%) 291 (59.1%) 0.008
Mental disorder subgroups
Depression 520 (63.5%) 758 (82.4%) –
Major depressive disorder 475 (91.3%) 745 (98.2%) –
Dysthymia 198 (38.1%) 210 (27.7%) –
Anxiety 608 (74.2%) 612 (66.5%) –
Panic disorder with agoraphobia 107 (17.6%) 130 (21.2%) –
Panic disorder without agoraphobia 140 (23.0%) 149 (24.3%) –
Social phobia 306 (50.3%) 266 (43.4%) –
Generalized anxiety disorder 166 (27.3%) 259 (42.3%) –
Agoraphobia without panic disorder 125 (20.6%) 109 (17.8%) –
Using psychiatric medication in recent 2
yearsd
324 (39.6%) 195 (21.1%) 23 (4.7%)
Somatic diseasesd
Diabetes 52 (6.3%) 45 (4.9%) 17 (3.5%) 0.066
Stroke 12 (1.6%) 17 (1.8%) 12 (2.4%) 0.42
Arthritis or arthrosis 193 (23.6%) 160 (17.4%) 86 (17.4%) 0.002
Chronic none specific lung disease 118 (14.4%) 110 (12.0%) 45 (9.1%) 0.019
Rheumatism (fibromyalgia, SLE,
rheumatoid arthritis)
87 (10.6%) 53 (5.8%) 14 (2.8%) <0.001
Tumor 50 (6.1%) 64 (7.0%) 27 (5.5%) 0.52
Ulcer 16 (2.0%) 10 (1.1%) 2 (0.4%) 0.047
Intestinal disorders 166 (20.3%) 134 (14.6%) 35 (7.1%) <0.001
Allergies (hay fever, eczema) 267 (32.6%) 312 (33.9%) 140 (28.5%) 0.22
Thyroid disease (Graves disease,
hyperthyroidism)
35 (4.3%) 35 (3.8%) 17 (3.5%) 0.76
Head injury 20 (2.4%) 22 (2.4%) 5 (1.0%) 0.15
Sickness 1 week prior to blood drawnd
Fever 38 (4.6%) 42 (4.6%) 18 (3.7%) 0.69
Cold 233 (28.4%) 252 (27.4%) 135 (27.4%) 0.87
aDepression and/or anxiety present in the 6 months prior to assessment.
bLifetime depression and/or anxiety diagnosis, but not in the 6 months prior to assessment.
ct test is used for comparing the age difference between groups and the chi-square test is used for comparison of gender, somatic diseases, and sickness prior to
blood drawn between different groups.
dThe number is dependent on questionnaires when the answer is “yes”.
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(1:40 diluted in 1% BSA) and a commercially available
antibody targeting a specific antigen for 1 h at room
temperature. A complete overview of the antibodies used
can be found in supplementary Table 1. Human IgG was
visualized using goat anti-human IgG Fcγ Alexa488 and
cell nuclei were stained with 4’, 6-diamidino-2-
phenylindole in the mounting medium. See supplemen-
tary methods for details regarding the primary and sec-
ondary antibodies used for the detection of the neuronal
antigens as well as for additional methodological infor-
mation for this section.
Live cell-based assay was performed as previously
described for fixed CBA with the difference that antigens
were expressed with fluorescent reporter proteins if
available and human serum was incubated with living cells
instead of fixed and permeabilized cells. Transfected HEK
cells were incubated with human serum (1:50 diluted in
DMEM with 1% BSA and 25mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid at room temperature for
1 h. Cells were then fixed with 3.6% formaldehyde and
incubated with the corresponding secondary antibodies
(Supplementary Table 1), mounted and analyzed as
described above.
Pre-absorption test by live CBA and IHC
To validate if an IHC pattern was given by autoantibodies
detected by live CBA in each of the CASPR2-positive
samples, a pre-absorption test was performed as descri-
bed29. For absorption of CASPR2 antibodies, 500 µl of
CASPR2 antibody-positive plasma or other plasma samples
as controls (diluted 1 in 200) were added to the CASPR2
transfected HEK cells growing in 24 well plates and incu-
bated for 1 h at 37 °C. Then the supernatant was collected
and applied to the next well of the CASPR2 transfected
HEK cells. These procedures were repeated four times.
Afterwards, the supernatant was collected to perform IHC
staining on rat brain slice as explained above.
Staining on live neurons
To test if autoantibodies directly target neuronal surface
proteins, rat hippocampal neuronal staining was per-
formed as described previously27,30, with small modifica-
tions. In brief, neurons were incubated with patients’ sera,
followed by incubation with anti-human IgG fluorescent-
labeled secondary antibody (supplementary Table 1) for
1 h and mounted with mounting medium containing
DAPI; all the steps were performed at room temperature.
A positive control with autoantibodies to NMDAR from
an encephalitis patient and negative controls from healthy
individuals were included. The results were scored as
negative, weak positive or strong positive according to the
fluorescent signal on the surface of neurons. Neuronal
staining in positive samples was confirmed using an anti-
microtubule-associated protein 2 (MAP2, Millipore,
AB5622, 1:1500 diluted in 1% BSA, after a 10min per-
meabilization step), followed a by goat anti-rabbit IgG
Alexa 594 staining.
Statistical analysis
Fisher’s exact test was used to compare the prevalence
of positive IHC samples between groups (disorders and
controls, or current disorder, remission and controls).
Chi-Square test was performed for categorical values (sex)
and ANOVA for continuous values (age). All analyses
were performed using IBM SPSS Statistics version 23.0.
The differences were considered statistically significant
when P values were below 0.05.
Results
IHC studies: 2.2% of the samples were found positive with
11 novel patterns
Plasma samples from 2231 individuals were initially
tested by IHC on rat brain tissue, as described27. Overall,
106 (4.8%) samples had scores of 1 or higher, of which 56
(2.4%) samples had score 1 (borderline), 42 (1.8%) had
score 2 (weak positive), and 8 (0.4%) had score 3 (strong
positive) (Table 2). Within the positive samples, 11 novel
staining patterns were identified; they were clearly dif-
ferent from reported patterns of known NSAbs associated
with autoimmune encephalitis12,31 (Fig. 1, pattern A–K;
and Supplementary Fig. 2).
From the current depression or anxiety group, 44 out of
819 samples (5.3%) had scores of 1 or higher. From the
depression or anxiety in remission group, 37 out of
920 samples (4.0%) had scores of 1 or higher and from the
control group, 25 out of 492 samples (5.1%) had scores of
1 or higher. The percentages of positive samples were not
significantly different between the groups (Table 2).
Interestingly, all eight samples with score 3 were found in
the depression or anxiety groups (current or in remission,
see Table 3, P1–8) and none in the control group (6/819
vs 2/920 vs 0/492, P= 0.071, Table 2).
Staining on live neurons: seven out of eight individuals
with unknown NSAbs had current anxiety or depression
Autoantibodies to neuronal membrane proteins are
much more likely to be pathogenic than autoantibodies to
intracellular antigens. As both could bind to brain tissue by
IHC, we tested all the 106 samples that had IHC scores of 1
or higher for NSAbs on live-cultured neurons at a dilution
of 1:50 (see Table 2). Overall, NSAbs were present in 8 out
of 106 samples. From the current depression or anxiety
group, 7 out of 44 samples were positive (P2–6, P9, and
P10, see Table 3; three of the strongest stainings are shown
in Fig. 2). All seven had anxiety, two of them also had
depression. In the depression or anxiety in remission
group, none of the 37 samples had NSAbs. From the
control group 1 out of 25 samples was positive (C1, see
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Table 3). These eight samples accounted for 0.4% of
the whole cohort. The prevalences of NSAbs in each of the
groups (current depression or anxiety group vs depression
or anxiety in remission group vs controls) differed sig-
nificantly (7/819 vs 0/920 vs 1/492, P= 0.006, Fisher’s
exact test). The NSAbs were found more frequently in the
current depression or anxiety group compared with the
group in remission (7/819 vs 0/920, P= 0.015, with Bon-
ferroni correction of multiple comparisons), whereas there
was no significant difference between the current depres-
sion or anxiety group and the controls (7/819 vs 1/492,
P= 0.27), nor between the group in remission and the
controls (0/920 vs 1/492, P= 0.35).
CBA studies: autoantibodies to known neuronal antigens
were rarely present
To test if plasma samples contained autoantibodies to
known neuronal antigens, all 106 samples with IHC
scores of 1 or higher were screened for NSAbs using both
fixed and live CBAs, and tested for GAD65 and GAD67
antibodies by fixed CBA (Table 2). By fixed CBAs, two
samples were found positive. One sample (P11, see Table
3) was positive for anti-CASPR2 and the other one (P12,
see Table 3) was positive for both anti-GAD65 and
anti-GAD67. P12 had the corresponding IHC pattern
(image not shown), but this was not the case for P11
(Supplementary Fig. 3). By live CBA, 13 samples were
found positive: 8 for CASPR2 (including P11), 1 for LGI1,
1 for GABAAR, and 3 for GABABR. All were very weakly
positive (titration between 1:20 to 1:250) compared to the
positive control samples from encephalitis patients we
used. None of these live CBA-positive samples had tested
positive for NSAbs on live neurons, or presented a cor-
relating antigen-binding pattern on rat brain IHC. In
addition, a pre-absorption assay was performed for all
CASPR2-positive samples identified by live CBA. Plasma
was first pre-absorbed on (human) CASPR2 transfected
cells and subsequently incubated on rat brain (Supple-
mentary Fig. 3). However, the staining intensity in IHC
was not reduced, indicating that the immunoreactivity to
the hippocampus was not caused by autoantibodies
binding to human CASPR2.
Except for P11, the very weak positive cases found by
live CBAs did not correlate with any other tests and
therefore the live CBA results were considered incon-
clusive. To summarize, the studies detected one patient
with confirmed CASPR2 and one with confirmed GAD
antibodies.
Table 2 Prevalence of neuronal autoantibodies in the 2231 NESDA respondents.
Current depression or anxiety
(N= 819)a
Depression or anxiety in
remission (N= 920)b
Control group
(N= 492)
P value
IHC score 1, 2, or 3c 44 (5.4%) 37 (4.0%) 25 (5.1%) N/Sd
Borderline (Score 1) 23 (2.8%) 19 (2.1%) 14 (2.8%) N/S
Weak positive (Score 2) 15 (1.8%) 16 (1.7%) 11 (2.2%) N/S
Strong positive (Score 3) 6 (0.7%) 2 (0.2%) 0 N/S (0.071)
Positive by IHC and staining on live
neurons (Novel NSAbs)e
7 (0.9%) 0 1 (0.2%) 0.006
Positive by IHC and fixed CBAf 1 (0.1%) 1 (0.1%) 0
Anti-CASPR2 0 1 (0.1%) 0 N/S
Anti-GAD65/67 1 (0.1%) 0 0 N/S
Othersg 0 0 0 N/S
Positive by IHC and live CBAf 3 (0.4%) 8 (0.9%) 2 (0.4%)
Anti-NMDAR/Anti-AMPAR 0 0 0 N/S
Anti-CASPR2 1 (0.1%) 5 (0.5%) 2 (0.4%) N/S
Anti-LGI1 0 1 (0.1%) 0 N/S
Anti-GABAAR 0 1 (0.1%) 0 N/S
Anti-GABABR 2 (0.2%) 1 (0.1%) 0 N/S
aDepression and/or anxiety present in the 6 months prior to assessment.
bLifetime depression and/or anxiety diagnosis, but not in the 5 months prior to assessment.
cIn all, 2231 were tested by IHC.
dN/S: no significant difference. α= 0.05
e,fSamples with IHC score 1, 2, or 3 (N= 106) were further tested by staining on live neurons and CBA.
gAnti-NMDAR, anti-AMPAR, anti-LGI1, anti-GABAAR, and anti-GABABR.
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Cross-validation of autoantibody detection
The 18 samples that gave the strongest staining intensity
by IHC (the eight samples described above as positive on
live neurons were all included) and two negative samples
were retested in a reference diagnostic laboratory accord-
ing to established diagnostic approach for autoimmune
encephalitis (the test conditions and strategy are described
in the supplementary methods). By IHC on rat brain, the
same staining patterns and intensities were reproduced for
all samples (Supplementary Fig. 4). Staining patterns in
11 samples were identified as potentially relevant for
NSAbs and these samples were therefore further tested on
live neurons with a sample dilution of 1:200. These
11 selected samples included seven out of the eight that
had been previously identified to contain novel NSAbs
(P10 was not included). The presence of NSAbs to cultured
neurons was confirmed for three individuals (P2, P3, and
P9, Supplementary Fig. 4).
Based on the observed IHC staining patterns, seven
samples were then also tested by fixed CBA for auto-
antibodies to NMDAR, LGI1or GAD65/67 at a 1:200
dilution in each case, but none of the samples tested
positive (Supplementary Fig. 4).
Analysis of immunoreactivity of NSAbs and clinical
correlations
We aimed to characterize the seven individuals with
NSAbs and coexisting anxiety or depression by further IHC
tests and by analyzing their clinical information (see Table
3). All these patients were diagnosed with current anxiety,
Fig. 1 Novel rat brain immunohistochemistry patterns of autoantibodies from NESDA cohort individuals. A–K represent 11 unique IHC
staining patterns of plasma autoantibodies on sagittal sections of rat brain. For each pattern, also a larger magnification of the hippocampus is
shown. Arrows indicate regions with the strongest immunoreactivity in the hippocampus or cerebellum. The CA1, CA3, dentate gyrus (DG), and
subiculum (Sub) regions of the hippocampus are labeled in A. l represents a negative staining result from a healthy individual. Scale bar= 500 µm.
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whereas the anxiety sub-diagnoses were diverse (three had
agoraphobia, two had generalized anxiety disorders, one had
social phobia, and one had panic without agoraphobia). The
BAI (Beck Anxiety Inventory) and the IDS (Inventory for
Depressive Symptomatology) were not different compared
with other patients with current anxiety or depression (data
not shown). None of them had used anti-depressant drugs
in the 2 years before blood sampling. One patient had breast
cancer, had undergone an operation and received che-
motherapy. The control individual that had tested positive
for NSAbs (C1) had a history of injury (overloading of the
knee) without other systemic health conditions.
Individuals with NSAbs and current anxiety or depres-
sion had IHC staining patterns B, C, E, and G, whereas
pattern K was only found in the control individual
with NSAbs.
Because not only the presence but also a high concentra-
tion of NSAbs can be an indicator of autoimmune brain
disease32, we titrated plasma samples by brain IHC, as this
method is more sensitive compared with immunofluorescent
staining on live neurons for unidentified autoantibodies
based on our experience. The titers of the seven patients with
current anxiety and NSAbs were equal or above 1:800,
whereas the control sample had a titer of 1:400.
Table 3 Characteristics of the individuals with autoantibodies giving score 3 by IHC or positive for known or to novel
NSAbs at wave 3.
No. Sex Age (year) IHC
score/
patterna
Titer by IHC CBA Staining
on live
neurons
Diagnosisb Anxiety/
depression
onset
age (year)
Anti-
depressants
usage
during the
last 2 years
Fever/
coldc
Chronic comorbidities
P1 Male 66 3/A Not tested Negative Negative Remitted
depression
–/35 No No Rheumatism: fibromyalgia;
hay fever, house dust allergy
P2 Female 46 3/B 12800 Negative Positive Current anxiety 8/– No Cold Hay fever
P3 Male 55 3/B 6400 Negative Positive Current anxiety,
remitted
depression
(single episode)
53/14 No Cold Hypertension
P4 Female 58 3/B 800 Negative Positive Current anxiety
and depression
56/56 No Cold Chronic bronchitis; diarrhea;
eczema; psoriasis
P5 Female 57 3/C 3200 Negative Positive Current anxiety 55/– No Cold Hypertension; breast cancer;
eczema; arthritis; renal pelvic
inflammation with
encapsulated kidney stone;
chronic heart conditions
(unspecified)
P6 Female 31 3/C 3200 Negative Positive Current anxiety,
remitted
depression
(single episode)
29/20 No No No
P7 Female 58 3/C Not tested Negative Negative Remitted
anxiety and
depression
16/36 No No Diabetes; arthritis; benign
connective tissue tumor;
allergy
P8 Male 66 3/D Not tested Negative Negative Current
depression
–/45 Yes No No
P9 Male 56 2/E 1600 Negative Positive Current anxiety,
remitted
depression
(single episode)
48/28 No No Eczema
P10 Female 36 2/F 1600 Negative Positive Current anxiety
and depression
35/34 No No Chronic heart conditions
(unspecified); ligament injury
P11 Male 53 1/H Not tested CASPR2
positive
(live and
fixed CBA)
Negative Remitted
depression
–/51 Yes No Hypertension; asthma;
arthritis; hay fever;
P12 Male 66 2/GAD
pattern
Not tested GAD65/67
positive
Negative Current
depression
–/61 No No Diabetes, hypertension;
arteriosclerosis, heart disease,
chronic bronchitis;
rheumatism; arthritis;
constipation;
C1 Male 20 2/K 400 Negative Positive None
(Control group)
–/– No No Injury (overloading of
the knee)
aIHC novel pattern: 11 different novel IHC patterns were found in this study (see Fig. 1, A–K).
bCurrent: diagnosed with depression and/or anxiety within 6-month when blood samples were collected. Remitted: diagnoses with depression and/or anxiety earlier
in life but no diagnoses of depression or anxiety within 6-month when blood samples were collected.
cHad a fever or a cold in the past week before the blood sample was drawn based on questionnaires.
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As depression and anxiety are often chronic conditions,
we tested additional plasma samples that were donated 2
years earlier (“Wave 1”) and 4-year later (“Wave 5”) by
the individuals that had NSAbs at Wave 3. We noted no
obvious correlation between changes of antibody titer by
IHC and the presence of disease (anxiety and/or
depression). In one individual (P2, see Supplementary
Fig. 5) the NSAb and IHC reactivity was not found in
earlier or later plasma samples, which coincided with the
absence of anxiety and depression at these time points. In
the remaining six individuals with anxiety or depression,
the IHC staining patterns were stable over time in all
available plasma samples (Supplementary Fig. 5, P3–6,
P9, and P10). In one control individual (C1), NSAbs were
found in the plasma of Wave 1 and Wave 3, but not
of Wave 5.
Discussion
To our knowledge, this is the largest study so far to
investigate whether neuronal autoantibodies, especially
NSAbs, are associated with depression or anxiety. Our
results indicate that these autoantibodies are not present in
the vast majority of individuals with these disorders, which
aligns with findings from earlier reports23,25,33. Never-
theless, none of the previous studies investigated the pre-
sence of potentially novel NSAbs. Our data show that a
small fraction (0.9%) of patients with current anxiety or
depression had autoantibodies targeting yet undefined
surface antigens, compared with individuals with depres-
sion or anxiety in remission where no such autoantibodies
were found.
We need to interpret these findings carefully and to
consider their significance because novel NSAbs could be
Fig. 2 Immunofluorescence staining on primary hippocampal live neurons of plasma samples from selected individuals. Neurons were
stained with anti-MAP2 (red), autoantibodies were stained with anti-human IgG (green) and nuclei were stained with DAPI (blue). Serum from an
encephalitis patient with NMDAR autoantibodies was used as a positive control (“Pos”), plasma from a healthy individual was used a negative control
(“Neg”). Plasma samples from Case 2, Case 5, and Case 9 showed clear immunoreactivity to live neurons. Scale bar= 50 µm. Regions in white boxes
are shown at higher magnification on the right panels; these show a speckled human IgG staining along the dendrite. Scale bar= 20 µm.
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innocent bystanders unrelated to the disorder. In this
context, false positives could also pose a considerable
problem for the interpretation of laboratory data, especially
for diseases with low prevalence such as NSAbs-associated
disorders33,34. Weak positive samples were found in all
groups by IHC or live CBA, which could not be confirmed
by a second method. These autoantibodies were not related
to depression or anxiety but may be a result of unrelated
autoimmune conditions since individuals with somatic
diseases were not excluded from the groups.
The use of multiple techniques in tandem, e.g., IHC
followed by neuronal staining, is commonly used to
increase the specificity of antibody detection for the
diagnosis of autoimmune encephalitis26. When analyzing
the anxiety and depression cohort, only seven samples
fulfill the criteria to be both positive by IHC and also by
staining on live neurons. These samples were compre-
hensively screened by CBAs, and so far, the targeted
surface antigens remain unknown. Notably, all were from
current anxiety patients (with or without depression), but
none was from a patient in remission. However, in the
present study, one sample (0.2%) with NSAbs was also
found in the control group, which questions the clinical
relevance of those novel NSAbs found in the depression
or anxiety groups. Our explanation is that the NSAbs
present in the depression or anxiety groups targeted dif-
ferent neuronal surface proteins from the one found in
the control group because they gave obviously different
staining patterns on brain tissue. Interestingly, two pat-
terns (patterns B and C) were repeatedly found in patients
with depression and anxiety disorders. These patterns
were absent in our previous study where we used a similar
strategy to detect NSAbs in individuals with psychotic
disorders (n= 621) and control participants (n= 257
blood donors)27, which supports the notion of genuine
novel NSAbs in the current study.
In a reference laboratory, the presence of novel NSAbs
was confirmed in three samples, when analyzed according
to the procedure and evaluation criteria followed routi-
nely for diagnosing autoimmune encephalitis. If we con-
sidered only these three sera, our study lacked the power
to detect significant differences between the tested
groups. Some IHC staining patterns we identified were
considered unspecific for NSAbs associated with auto-
immune encephalitis. Moreover, the test of NSAbs in
cultured neurons used a higher sample dilution in the
reference laboratory, compared to the one we used. These
differences highlight the importance of confirmational
studies, the standardization of methods and interpreta-
tions, especially when using patient cohorts with different
characteristics/symptoms.
This cohort study has several limitations: (1) not all the
known NSAbs that have been reported to be associated
with neurological diseases were tested by CBA in this
study [for instance, not tested were antibodies to D2DR,
mGluR5, mGluR1, neurexin-3α, IgLON5, DNER (Tr),
Glycine receptor and amphiphysin]. But the presence of
high levels of such antibodies was excluded empirically
based on the IHC patterns. (2) As we chose the strategy to
screen all plasma samples first by IHC, we cannot exclude
the possibility that we missed samples with low titer or
low-affinity NSAbs that can only be detected by CBA. (3)
As mentioned, we only analyzed peripheral blood sam-
ples, whereas no cerebrospinal fluid was available, so the
question as to whether identified NSAbs would pass the
blood–brain–barrier remains to be investigated.
To conclude, we suggest that further studies aiming to
validate these findings should focus on individuals cur-
rently suffering from anxiety (with or without depression)
by using cerebrospinal fluid and blood samples. Con-
sidering the low prevalence of the novel NSAbs found in
this study, identification of the autoantigens, e.g., by mass
spectrometry or a longitudinal study by timely follow-up
would help to further reveal the possible clinical relevance.
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